Optometrists can prescribe MiYOSMART with even more confidence with HOYA revealing new eight-year data. No other clinical study on myopia management spectacle lenses has tracked outcomes over such an extended period.
“First mover advantage.” It’s a term referring to the competitive edge a company gains by introducing a product ahead of its competitors. For HOYA in myopia management, this early entry hasn’t just built brand recognition and customer loyalty — it’s enabled the company to consistently raise industry standards.
The lens manufacturer’s MiYOSMART product first launched in Australia and New Zealand in 2020, and during those five years, the ophthalmic landscape has seen a wave of other myopia spectacle lens options.
But while companies have been working to bring their own products to market, HOYA has forged ahead with its product development, making MiYOSMART available in clear, polarised, and photochromic options, and increasing the power range.
Most importantly, it has been building an evidence base that reinforces the long-term effectiveness of the lens, as well as its performance in key areas including combination treatment with atropine, across various ethnicities and age groups, and in pre-myopes.
Many of these key updates were presented at the company’s scientific program, ‘Exploring new frontiers in myopia management with MiYOSMART’, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, in May 2025.
One of the headline read-outs was the eight-year data on MiYOSMART, which incorporates Defocus Incorporated Multiple Segments (DIMS) technology, stemming from the widely accepted peripheral hyperopic defocus theory. This makes it the world’s longest-running clinical study on myopia management spectacle lenses.
It showed that continuous DIMS spectacle lens wear significantly reduced myopia progression (-1.00 D ± 0.41 D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently over the full eight years (n=11) of follow-up.¹
The results – from Lam CSY et al – are an extension of the important two-year randomised clinical trial showing that daily use of MiYOSMART slowed myopia progression on average by 60% compared to wearing standard single vision spectacle lenses.²
The latest eight-year evidence demonstrates that wearing MiYOSMART spectacle lenses continuously and long-term may improve myopia management outcomes, the company says.
Dr Natalia Vlasak, global head of medical and scientific affairs at HOYA Vision Care, says:
“This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest.
“These findings emphasise the life-changing value of long-term adherence, providing crucial information and guidance for eyecare professionals and parents committed to protecting children’s vision health for the future.”
Meanwhile, the first 12-month data read-out from the ASPECT randomised controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.3 The mean change in axial length was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4
“Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression, marking a positive step towards more personalised, powerful treatment strategies in myopia management that suit the unique needs of each child,” says Dr Vlasak.
As optometrists place more emphasis on preventing myopia in the first place, at ARVO HOYA also released outcomes from a first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in five- and six-year-old children.
This indicates DIMS technology may offer a protective effect against the development of myopia in this population, says HOYA.
Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06 D compared with -0.15 D in a control group.
While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable.
The company says these promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone onset in pre-myopic preschoolers, laying the groundwork for future research.5
“We want eyecare professionals to feel confident in our MiYOSMART solutions when managing childhood myopia in their everyday practice,” says Mr Ulli Hentschel, HOYA Lens Australia’s training and development manager.
“That’s why we have generated a robust and wide spectrum of evidence, with the aim of empowering eyecare professionals to meet the diverse needs of patients.”
And there’s more data to back that up — perhaps the most compelling of it all: to date, more than 12 million MiYOSMART spectacle lenses have been sold worldwide in over 40 countries.
References
1.Leung TW, et al. Comparison of Myopia Progression in Individuals Wearing Defocus Incorporated Multiple Segments (DIMS) Spectacle Lenses for Eight Years versus Shorter Durations. Poster number A0113. Presented 6th May, ARVO 2025.
2. Lam CSY, Tang WC, Tse DY, Lee RPK, Chun RKM, Hasegawa K, Qi H, Hatanaka T, To CH. Defocus Incorporated Multiple Segments (DIMS) spectacle lenses slow myopia progression: a 2-year randomised clinical trial. British Journal of Ophthalmology. Published Online First: 29 May 2019. doi: 10.11.36/ bjophthalmol-2018-313739.
3. Guemes-Villahoz N, et al. Atropine and Spectacle lens Combination Treatment (ASPECT): 12-month results of a randomised controlled trial for myopia control using a combination of Defocus Incorporated Multiple Segments (DIMS) lenses and 0.025% atropine. Poster number B0466 . Presented 7th May, ARVO 2025.
4. Garcia EH, et al. Vision-related quality of life in myopic children using combination treatment with atropine and DIMS (Defocus Incorporated Multiple Segments) spectacle lenses: 12-month results. Poster number A0297. Presented 5th May, ARVO 2025.
5. Yang HY, Tsai DC. Efficacy of Defocus Incorporated Multiple Segments (DIMS) Lenses in Retarding Myopic Shifts Among Pre-Myopic Preschoolers: Nine-Month Results of a Pilot Study. Poster number A0104. Presented 7th May, ARVO 2025.
More reading
New HOYA coating cuts UV transmission through Sensity lenses
50 years of HOYA . . . and still evolving
